Target intelligence / Profile preview

Peroxisomal fatty acid β-oxidation pathway

Molecular classification
Other (metabolic pathway, contains various enzymes—acyl-CoA oxidase, bifunctional proteins, thiolase, and fatty acid transporters)
01

Overview

The peroxisomal fatty acid β-oxidation pathway is a cellular metabolic process responsible for the initial breakdown and shortening of very long-chain and branched-chain fatty acids. Its function is distinct from mitochondrial β-oxidation, as it specializes in substrates that cannot be processed by mitochondria, generating acetyl-CoA and hydrogen peroxide (H₂O₂) as byproducts. Key enzymes include acyl-CoA oxidase, bifunctional proteins, and thiolase, with regulation governed by peroxisome proliferator-activated receptor alpha (PPARα). Disruption or dysregulation of this pathway contributes to metabolic diseases such as fatty liver, steatohepatitis, liver cancer, and certain neurological disorders due to accumulation of substrate fatty acids or excessive ROS production[1][2][3][5].

Other names
Peroxisomal β-oxidationperoxisomal fatty acid oxidation
02

Mechanism of action

Induction of pathway activity by peroxisome proliferators (drugs increase enzyme expression/activity) Attenuation of oxidative stress via antioxidants

03

Biological functions

Fatty acid catabolismCellular lipid homeostasisReactive oxygen species (ROS) productionRegulation of metabolic flux (feedback on lipolysis via ROS signaling)
04

Disease associations

Metabolic disorders (e.g., fatty liver disease, pseudoneonatal adrenoleukodystrophy)Hepatic steatosis and steatohepatitisLiver cancerNeurological diseases associated with VLCFA accumulation
05

Safety considerations

Excess ROS production (hydrogen peroxide) leading to oxidative stress and tissue damageHepatotoxicity and glial degeneration in case of gene defects or drug-induced overactivation
06

Interacting drugs

Peroxisome proliferator-activated receptor agonists (e.g., clofibrate induces the pathway)

1 more in the full profile.

07

Biomarkers

Plasma very long-chain fatty acids (VLCFA) (accumulation indicates defects)Acyl-CoA oxidase 1 (ACOX1) enzymatic activityPeroxisomal ROS levels

Beyond the preview

Go deeper on Peroxisomal fatty acid β-oxidation pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peroxisomal fatty acid β-oxidation pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call